The Benefits of Targeted Therapy for Lung Cancer

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

This is the first time that one of these oral what we call targeted therapies has been used in this early setting and it's improved survival. There was a 51% decrease in death with this pill versus the placebo. Only about 15 to 50 percent depending where you live have this abnormality so we're plucking off a good chunk but there's still a lot of work to do to get the other patients we are working on.

Ian Sample speaks to the Guardian’s health editor, Andrew Gregory, and Dr Roy Herbst about the world’s biggest annual gathering of oncology professionals. Each year’s event features a mass of new research, and 2023 was no exception. What were the standout advances, and could they lead to permanent changes in the way we treat, think about and live with cancer?. Help support our independent journalism at theguardian.com/sciencepod